Malignant Solid Tumor
Conditions
Keywords
Metastatic Solid Neoplasm, Advanced Solid Tumor, Genomic alteration, Targeted therapy, Cabozantinib, Ribociclib, HDM201, Alectinib, Trametinib, Dabrafenib, Avapritinib
Brief summary
This trial is a multicenter, open-label, biology driven, phase II study using a sequential Bayesian design, aiming to assess the efficacy and safety of different Matched Targeted Therapy (MTT) in independent and parallel cohorts of treatment. Patients will be assigned to a treatment cohort based on molecular alterations/characteristics detected on tumor sample from primary tumor or metastatic lesion. In this protocol, several MTTs treatment cohorts are planned. This study is designed with the flexibility to open new MTTs treatment cohorts and to close existing MTTs treatment cohorts that demonstrate no clinical benefit. Each treatment cohort will be driven separately even though procedures, quality control and reporting, will be common. The protocol will be amended in order to include new treatments or combinations that emerge as being of interest for patients with advanced/metastatic cancers. All eligible patients will receive study drugs as long as patient experiences clinical benefit in the opinion of the investigator, or until unacceptable toxicity, or until symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status, or withdrawal of consent. Patients will be permitted to continue study treatment after progressive disease according to RECIST v1.1 if they meet all of the following criteria and following validation of the Sponsor: * Evidence of clinical benefit as assessed by the investigators, * Absence of symptoms and signs (including worsening of laboratory values; e.g., new or worsening hypercalcemia) that indicate unequivocal progression of disease, * No decline in ECOG Performance Status (PS) that can be attributed to disease progression.
Interventions
DRUGHDM201
HDM201 120mg, Every 3 weeks, Per os
DRUGRibociclib
Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
DRUGCabozantinib
Cabozantinib, 60 mg /day, continuous, Per os
DRUGAlectinib
Alectinib, 600mg twice daily, Per os
DRUGRegorafenib
Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os
DRUGTrametinib
Trametinib 2 mg/day, continuous, Per os
DRUGDabrafenib
Dabrafenib 150 mg twice daily, Per os
DRUGAvapritinib
300 mg/day,continuous, Per os
Sponsors
Centre Leon Berard
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients aged of at least 18 years on day of signing informed consent. * Patients with histologically confirmed diagnosis of metastatic disease or unresectable locally advanced malignancy that is resistant or refractory to standard therapies or for which standard therapies does not exist or is/are not considered appropriate by the investigator. * A multidisciplinary molecular board must have recommended the specific MTT based on the following documented actionable alterations: * Cohort HDM201-Ribociclib : amplification of CDK6 and/or CDK4, and/or CDKN2A homozygous deletion, and/or amplification of CCND1 and/or CCND3 with no deletion/losses more than single copy of RB1 by copy number and P53 wild-type. * Cohort Cabozantinib : AXL, MET, VEGFR, VEGF, RET, ROS1, MER, TRKB, TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation and/or ROS1 translocation, and/or MET translocation. * Cohort Alectinib : Activating ALK alterations: translocation, or selected mutations, or activating rearrangements following validation by central molecular tumor board of Centre Léon Bérard. * Cohort Regoranib : Activating mutation and/or amplification and/or rearrangement of VEGFR1-3, TIE-2, KIT, RET, RAF1, BRAF (other than V600 mutations), CRAF, HRAS, PDGFR, FGFR1-2, FLT3 and/or CSFR1, and/or amplification of the ligands, and/or biallelic inactivation of SMAD4, following validation by central molecular tumor board of Centre Léon Bérard. * Cohort Trametinib : Activating mutation and/or amplification of KRAS (except all KRAS G12 mutations), NRAS, HRAS and/or MAP2K; and/or biallelic inactivation of NF1; and/or activating mutation PTPN11; and/or amplification or translocation of BRAF, and/or translocation RAF1 * Cohort Trametinib + Dabrafenib : BRAF V600 mutation. * Cohort Avapritinib : Activating mutations of KIT exon 17 or PDGFRA exon 18 associated or not to mutation on KIT exon 11 or PDGFRA exon 12/14 * Previously treated by at least one prior line of treatment in the advanced/metastatic setting except for specific tumor type with no standard treatment approved and reimbursed in France following sponsor approval. * Documented radiological disease progression as per RECIST v1.1 and presence of at least one measurable lesion according to RECIST 1.1 criteria based on screening tumor assessment. * Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale. * Adequate organ function * Adequate cardiovascular function * Specific toxicities related to any prior anti-cancer therapy must have resolved to grade ≤1 , except for alopecia (all grades), grade 2 neuropathy or anemia. * Unless infertility is proven, men must agree to use effective contraception * Women of child-bearing potential must have a negative serum pregnancy test within 7 days of first dose of study drug and agree to use effective contraception * Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study procedures as per protocol. * Patient must be covered by a medical insurance.
Exclusion criteria
* Patients amenable to therapy with curative intent. * Patients participating to another clinical trial with a medicinal product. * Patients previously treated with similar MTT meaning any agent targeting the same signaling pathways components. * Patients unable to swallow oral medication. * Patients with known hypersensitivity to excipients * Patients with symptomatic central nervous system (CNS) metastasis who are neurologically unstable or require increasing doses of corticosteroids or local CNS-directed therapy to control their CNS disease. * Patients with secondary malignancy unless this malignancy is not expected to interfere with the evaluation of study endpoints and is approved by the sponsor. Examples of the latter include: basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, localized prostate cancer, prior malignancy and no evidence of recurrence for ≥ 2 years. * Patients using, or requirement to use while on the study, or not respecting the minimal wash-out period of medications * Any clinically significant and/or uncontrolled medical disease that could compromise the patient's ability to tolerate study drug or would likely interfere with study procedures or results. * Patients with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Patients who are pregnant or breastfeeding women or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through after the last dose of trial treatment (depanding on cohort).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free rate after 3 months (12 weeks) of treatment | 3 months (12 weeks) | The proportion of patients with a complete response (CR), a partial response (PR) or a stable disease (SD) at 3 months (12 weeks). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response | Up to 3 years | Duration of response applies only to patients whose best overall response was a complete response or a partial response (CR or PR). It will be defined as the time from the date of first documented response (CR or PR) to the date of the first documented progression or death due to underlying cancer and censored at the date of the last adequate tumor assessment. |
| Progression Free Survival | Up to 3 years | The time from the date of the first study drug administration to the first documented progression according to investigator assessment of RECIST version 1.1 or death due to any cause |
| Objective response rate after 3 months (12 weeks) of treatment | 3 months (12 weeks) | The proportion of patients with a complete or a partial response (CR or PR) as best overall response at 3 months (12 weeks). |
| Percentage of long-term responders (> 6 months) | 6 months | The proportion of long term responders (\> 6 months) |
| Adverse Events | Up to 3 years | Nature, frequency and severity of Adverse Events (AEs), Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) graded using Common Terminology Criteria for Adverse Events (CTCAE) V5.0. |
| Overall survival | Up to 3 years | The time from the date of the first study drug administration to the date of death due to any cause |
Countries
France
Contacts
Primary ContactJean-Yves BLAY, MD
Backup ContactOlivier TREDAN, MD
Outcome results
None listed